Corporate & Investor Presentation

Why invest? - driving long-term shareholder value с Growth & Innovation Global leader in digital health for sleep and respiratory care Long-term growth opportunities 8,700+ patents and designs • • ~7-8% of revenue invested in R&D . 0000 Market Dynamics Underpenetrated markets in sleep and COPD Healthcare costs continue to increase Focus on improving patient outcomes Value-based technology solutions Financial Results Historical revenue and profit growth • Recurring revenue Operating excellence program Strong track record of disciplined capital deployment Total Shareholder Return (NYSE shares as of 12/31/2021): 1-yr 23% 3-yr 135% 5-yr 346% 5 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22 ResMed

View entire presentation